Bristol Myers (BMY) Squibb announced results from POETYK PsA-1 and POETYK PsA-2, the pivotal Phase 3 trials evaluating the efficacy and safety of Sotyktu in adults with active psoriatic arthritis.

Just a few weeks after its approval in the UK, Bristol-Myers Squibb’s new oral psoriasis therapy Sotyktu has been recommended for routine NHS in England and Wales. The National Institute for ...

(RTTNews) - Drug maker Bristol-Myers Squibb Co. (BMY) Monday announced positive topline results from two pivotal Phase 3 trials evaluating Sotyktu (deucravacitinib) in adults with active psoriatic ...

Bristol Myers Squibb (BMS) has announced positive topline results from two Phase III trials evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic ...

Bristol Myers Squibb said a pair of late-stage studies of its plaque psoriasis drug Sotyktu met their key goals in adults with active psoriatic arthritis. Bristol Myers on Monday said the two ...

BMS is angling to make Sotyktu the first TYK2 inhibitor approved in the indication. Takeda is close behind with its TYK2 inhibitor TAK-279, which the Japanese company believes can be the best-in ...